Aclaris Therapeutics, Inc.

As of August 8, 2025, Aclaris Therapeutics shows a mildly bullish trend with positive weekly indicators, despite mixed signals from daily moving averages and a year-to-date underperformance compared to the S&P 500.

As of March 12, 2018, Aclaris Therapeutics, Inc. is considered risky and overvalued, with a Price to Book Value of 1.15 and a P/E ratio of -4.8751, making it less attractive compared to peers like Evolus, Inc. and the S&P 500.

As of March 12, 2018, Aclaris Therapeutics, Inc. is considered overvalued with a "risky" valuation grade, highlighted by a negative P/E ratio of -3.53 and a year-to-date return of -43.95%, contrasting sharply with the S&P 500's 2.44%.

As of May 28, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD and KST, suggesting a cautious approach is advisable.

As of March 2022, Aclaris Therapeutics, Inc.'s management team includes Dr. Neal Walker as President and CEO, along with independent directors Mr. Vincent Milano, Dr. Maxine Gowen, Mr. William Humphries, Dr. Anand Mehra, and Mr. Christopher Molineaux.

Aclaris Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for immuno-inflammatory diseases. As of March 2025, it reported net sales of $1 million and a net loss of $15 million, with a market cap of $151.59 million.

As of Jun 18, Aclaris Therapeutics, Inc. has a market capitalization of 151.59 million, with net sales of 17.79 million and a net profit of -130.22 million over the last four quarters. The company reported shareholder's funds of 155.55 million and total assets of 220.33 million as of Dec 24.